Metastasectomy, intralesional resection, or stabilization only in the treatment of bone metastases from renal cell carcinoma

2016 ◽  
Vol 114 (2) ◽  
pp. 237-245 ◽  
Author(s):  
David W.G. Langerhuizen ◽  
Stein J. Janssen ◽  
Quirine M.J. van der Vliet ◽  
Kevin A. Raskin ◽  
Marco L. Ferrone ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Bone Metastases ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Intralesional Resection

Embolization of Pelvic Bone Metastases from Renal Cell Carcinoma

1984 ◽  
Vol 10 (6) ◽  
pp. 380-384 ◽  
Author(s):  
U. Zwergel ◽  
W. Knopp ◽  
H.U. Braedel
Keyword(s):  
Renal Cell Carcinoma ◽  
Bone Metastases ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Pelvic Bone

Cytological diagnosis of Xp11 translocation renal cell carcinoma: An unusual suspect in bone metastases from unknown primary malignancies

2020 ◽  
Vol 49 (1) ◽  
pp. 11-17
Author(s):  
Marco Montella ◽  
Renato Franco ◽  
Gabriella Aquino ◽  
Andrea Ronchi ◽  
Federica Zito Marino ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Bone Metastases ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Unknown Primary ◽  
Cytological Diagnosis

Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era

2017 ◽  
Vol 15 (3) ◽  
pp. 363-370 ◽  
Author(s):  
Sarathi Kalra ◽  
Jonathan Verma ◽  
Bradley J. Atkinson ◽  
Surena F. Matin ◽  
Christopher G. Wood ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Bone Metastases ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell

scholarly journals Clinical outcomes of 168 Chinese patients after local surgery for bone metastases arising from advanced renal cell carcinoma

Cancer ◽  
2020 ◽  
Vol 126 (S9) ◽  
pp. 2079-2085 ◽  
Author(s):  
Yi Dong ◽  
Zheng Wang ◽  
Xin Lu ◽  
Zhenjie Wu ◽  
Zongqin Zhang ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Bone Metastases ◽  
Cell Carcinoma ◽  
Clinical Outcomes ◽  
Renal Cell ◽  
Chinese Patients ◽  
Advanced Renal Cell Carcinoma ◽  
Local Surgery

scholarly journals A phase II study of palliative radiotherapy combined with zoledronic acid hydrate for metastatic bone tumour from renal cell carcinoma

2020 ◽  
Vol 51 (1) ◽  
pp. 100-105
Author(s):  
Hideyuki Harada ◽  
Naoto Shikama ◽  
Hitoshi Wada ◽  
Nobue Uchida ◽  
Miwako Nozaki ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Zoledronic Acid ◽  
Bone Metastases ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Palliative Radiotherapy ◽  
Level Increase ◽  
Skeletal Related Events ◽  
Acid Hydrate ◽  
Skeletal Related Event

Abstract Purpose Palliative radiotherapy is the standard of care for bone metastases. However, skeletal-related events, defined as a pathologic fracture, paraplegia, surgery or radiotherapy for local recurrence, or severe pain in previously irradiated bone with radio-resistant histology type still present high incidence. The primary objective of this study was to determine whether zoledronic acid hydrate and palliative radiotherapy could prevent local skeletal-related events. Methods Eligible patients with bone metastases from renal cell carcinoma were treated with zoledronic acid hydrate every 3 or 4 weeks and concurrent palliative radiotherapy of 30 Gy in 3 Gy fractions. The criteria for radiotherapy were established by the treating physician, but patients with complicated bone metastases (impending pathological fracture or spinal cord compression) which needed immediate surgery were excluded. The primary endpoint was the local skeletal-related event-free survival rate at 1 year. Results Twenty-seven patients were included in the study. The median age was 65 (range, 50–84) years. Radiotherapy dose was 30 Gy for all patients except 1 whose radiotherapy was terminated due to brain metastasis progression at 18 Gy. Zoledronic acid hydrate was administered in a median of 12 (range, 0–34) times. The median follow-up period was 12 months and 19 months in patients who were still alive. Of 27 patients in the efficacy analysis, the 1-year local skeletal-related event-free rate was 77.6% (80% confidence interval, 66.2–89.0). Common grade 3 toxicities were hypocalcemia (1 [4%]), sGPT level increase (1 [4%]) and sGOT level increase (1 [4%]). There was no grade 4 or 5 toxicity. Conclusion Zoledronic acid hydrate administration and palliative radiotherapy were a well-tolerated and promising treatment reducing skeletal-related events for bone metastases from renal cell carcinoma.

scholarly journals Skeletal Complications in Patients with Bone Metastases from Renal Cell Carcinoma and Therapeutic Benefits of Zoledronic Acid

2004 ◽  
Vol 10 (18) ◽  
pp. 6397S-6403S ◽  
Author(s):  
Allan Lipton ◽  
Alejandro Colombo-Berra ◽  
Ronald M. Bukowski ◽  
Lee Rosen ◽  
Ming Zheng ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Zoledronic Acid ◽  
Bone Metastases ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Therapeutic Benefits ◽  
Skeletal Complications
Sign in / Sign up

Export Citation Format

Share Document